A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histologic subgroups for helicobacter pylori eradication in a developing country

Helicobacter

Volumn 14, Issue 2, 2009, Pages 100-108

  Fischbach, Lori Ann ^a   Bravo, Luis Eduardo ^b   Zarama, Guillermo Rosero ^b   Bravo, Juan Carlos ^b   Ojha, Priyadarshi Rohit ^a   Priest, Elisa Lynne ^a,c   Collazos, Tito ^b   Casabon, Lucy Alba ^b   Guerrero, Lorena Zambrano ^b   Singh, P Karan ^a   Correa, Pelayo ^d  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b UNIVERSIDAD DEL VALLE   (Colombia)

^c BAYLOR HEALTH CARE SYSTEM   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Amoxicillin; Clarithromycin; Clinical trial; Helicobacter pylori eradication; Metronidazole; Proton pump inhibitor; South America

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; ATROPHIC GASTRITIS; BITTER TASTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; DIARRHEA; DRUG EFFICACY; DRUG RELEASE; ERADICATION THERAPY; FEMALE; GASTRITIS; HEADACHE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COHORT STUDIES; COLOMBIA; DEVELOPING COUNTRIES; DRUG THERAPY, COMBINATION; FEMALE; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

EID: 62149088503     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2009.00667.x     Document Type: Article

References (24)

1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983 1 : 1273 5.
2. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984 1 : 1311 5.
3. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007 56 : 772 81.
4. Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidem 2002 31 : 128 39.
5. Frenck RW Jr., Clemens J. Helicobacter in the developing world. Microbes Infect 2003 5 : 705 13.
6. Kadayifci A, Buyukhatipoglu H, Cemil Savas M, Simsek I. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006 28 : 1960 6.
7. Dore MP, Leandro G, Readli G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori. Dig Dis Sci 2000 45 : 68 76.
8. van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999 94 : 1751 9.
9. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007 26 : 343 57.
10. Fischbach LA, Velhhuyzen Van Zanten S, Dickason J. Efficacy, adverse events and adherence related to first-line anti-Helicobacter pylori quadruple therapies: a meta-analysis. Aliment Pharmacol Ther 2004 20 : 1 12.
11. Fischbach LA, Correa P, Feldman M, et al. increased reflux symptoms after calcium carbonate supplementation and successful Helicobacter pylori treatment: results from a randomized clinical trial in a population with a high prevalence of multifocal atrophic gastritis. Dig Dis Sci 2003 48 : 1487 94.
12. Fischbach LA, Correa P, Ramirez H, et al. Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer. Aliment Pharmacol Ther 2001 15 : 831 41.
13. El-Zimaity Hala MT. Gastric atrophy, diagnosing and staging. World J Gastroenterol 2006 12 : 5757 62.
14. Kim JI, Park SH, Kim JK, Chung IS, Chung KW, Sun HS. The effect of nocturnal acid breakthrough on Helicobacter pylori eradication. Helicobacter 2002 7 : 331 6.
15. Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol 2007 21 : 315 24.
16. Dixon M, Genta R, Yardley J, Correa P. Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996 20 : 1161 81.
17. Tisazi L, Lnoviecs M. Comparison of diagnostic accuracy of non-invasive techniques in detection of H. pylori infection. European Helicobacter pylori Study Group XIth International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Gut 1998 43 : A54.
18. Tucci A, Poli L, Biasco G, et al. Helicobacter pylori infection and gastric function in patients with fundic atrophic gastritis. Dig Dis Sci 2001 46 : 1573 83.
19. Malfertheiner P, Peitz U, Treiber G. What constitutes failure for Helicobacter pylori eradication therapy? Can J Gastroenterol 2003 17 : 53B 57B.
20. Montori VM, Guyatt GH. Intention to treat principle. CMAJ 2001 165 : 1339 41.
21. Xia HH, Talley NJ. Natural acquisition and spontaneous elimination of Helicobacter pylori infection: clinical implications. Am J Gastroenterol 1997 92 : 1780 7.
22. Phillips PH, Whitehead MW, Doig LA, et al. Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe? Helicobacter 2001 6 : 151 6.
23. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002 16 : 1047 57.
24. Sörberg M, Hanberger H, Nilsson M, Björkman A, Nilsson LE. Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother 1998 42 : 1222 8.